Lyn Expression in Osteoblastic Osteosarcoma Tissues and Its Correlation with Clinicopathologic Factors
진민선, 강신광, 김민석, 최희승, 이정은, 김길호, 전대근, 고재수,
소속 상세정보
진민선 ( Jin Min-Sun )
원자력병원 병리학과
강신광 ( Khang Shin-Kwang )
울산대학교 의과대학 서울아산병원 병리과
김민석 ( Kim Min-Suk )
원자력병원 병리학과
최희승 ( Choi Hee-Seung )
원자력병원 병리학과
이정은 ( Lee Jung-Eun )
Korea Institute of Radiological and Medical Sciences
김길호 ( Kim Kil-Ho )
원자력병원 병리학과
전대근 ( Jeon Dae-Geun )
원자력병원 정형외과
고재수 ( Koh Jae-Soo )
원자력병원 병리학과
KMID : 0357920100440020125
Abstract
Background: The Src family kinases (SFKs) are involved in multiple aspects of tumorigenesis, such as, proliferation, migration, and angiogenesis, and are involved in the generation and progression of many types of tumors. Furthermore, dasatinib, a general SFKs inhibitor was recently approved for use in chronic myeloid leukemia. This study was performed to evaluate the expression of Lyn, a member of the SFKs, in osteosarcoma tissues.
Methods: One hundred and sixteen patients with osteoblastic osteosarcoma were selected for Lyn expression analysis. The correlation between Lyn expression in tumor sections and patients’ clinicopathologic characteristics and the prognostic significance of Lyn expression were evaluated.
Results: Lyn was found to be expressed in 52 of the 116 patients (44.8%), and Lyn positive tumor was found to be significantly associated with a lytic tumor pattern on plain radiographs (p = 0.04). Furthermore, those positive for Lyn showed longer metastasis free survival (5-year metastasis free survival, 65.2% for Lyn positive and 46.8% for Lyn negative; p = 0.06), though this was only marginally significant.
Conclusions: Lyn was found to be overexpressed in osteosarcoma tissues, and this overexpression was found to be correlated with osteolysis.
키워드
Osteosarcoma;Lyn protein-tyrosine kinase;Immunohistochemistry
원문 및 링크아웃 정보
등재저널 정보